Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Cytogenetic Risk: Updated Subgroup Analysis of CASTOR.
Journal of Clinical Oncology(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要